Why zero markup matters

Telehealth unit economics are usually decided in the pharmacy line, not the marketing line. Founders scrutinize acquisition cost to the dollar, then sign a platform agreement where the medication their patients take every month carries a 20 to 40 percent markup, plus a share of top-line revenue. Both numbers look tolerable at signing, when volume is small. Both scale with exactly the thing you are trying to grow.

How platforms price, and why

Most telehealth infrastructure vendors monetize one of three ways: a spread on medication, a percentage of revenue, or flat fees. The first two are popular because they are easy to sell — low fixed cost, "we only win when you win." The phrase is accurate in the least useful sense: the vendor wins a percentage of every win, forever, without its costs growing to match. A flat-fee model is harder to sell and much easier to build a company on top of, because your platform cost stays predictable while your revenue compounds.

A worked example

Run the numbers on a hypothetical weight-care brand: 1,000 active patients on a program billed at $199 a month, with medication that costs about $140 a month at wholesale.

On a marked-up model — say 30 percent on medication plus a 10 percent revenue share, both within the range commonly seen in white-label agreements:

• Medication markup: $42 per patient per month, or $42,000 a month across the book
• Revenue share: about $20 per patient per month, another $20,000
• Total platform take: roughly $62,000 a month, or $744,000 a year, before any fixed fees

On wholesale pass-through with flat fees, the same brand pays medication at cost, a fixed monthly platform fee, and a flat per-consult fee — on Tessic, $25 per completed consult. If those thousand patients generate around 400 consults a month (initial visits plus periodic follow-ups; stable subscription patients do not need one every month), the variable platform cost is $10,000. Even adding a $2,000 monthly platform fee, the flat model costs about a fifth of the marked-up one, and the gap widens with every patient you add, because consults grow far more slowly than patient count.

At 5,000 patients, the marked-up structure takes well over three million dollars a year — the economics of a co-founder, extracted by a vendor.

Percentages feel painless at low volume. They are priced against your success: the platform's take grows with your revenue while its costs stay flat.

Markup bends clinical incentives, too

There is a second-order cost. A platform that earns a spread on each fill has a financial opinion about what gets prescribed, how often, and at what dose. Formularies drift toward high-margin compounds; protocols drift toward more frequent fills. None of this requires bad intent — margin pressure does the steering on its own. Wholesale pass-through removes the platform from that decision entirely: the prescriber picks the medication, the pharmacy fills it at cost, and nobody upstream earns more if the dose goes up.

Questions to ask before you sign

• What is the medication markup, in percentage terms, in writing?
• Is there any revenue share, monthly minimum, or per-order fee that scales with volume?
• Can we see wholesale acquisition cost, or is pricing a black box?
• What do our per-unit economics look like at ten times current volume?
• If we leave, what do our patients pay for the same medication the next month?

A vendor with clean economics will answer all five in one email. A vendor that earns its margin in the spread will need a call to walk you through it.

Tessic's model is the boring version: a flat monthly fee, $25 per completed consult, medication at wholesale with 0% markup, and no revenue share, month to month after setup. We publish it because founders should be able to model their clinic's economics at 10,000 patients before they have 100 — and because the model that survives that spreadsheet is the one that deserves to run your clinic.